€5.44
2.51% today
Paris, Apr 02, 05:35 pm CET
ISIN
FR0012333284
Symbol
ABVX
Sector
Industry

Abivax SA Stock price

€5.44
-1.46 21.16% 1M
-3.86 41.51% 6M
-1.32 19.53% YTD
-7.98 59.46% 1Y
-18.76 77.52% 3Y
-11.68 68.22% 5Y
-15.56 74.10% 10Y
Paris, Closing price Wed, Apr 02 2025
-0.14 2.51%
ISIN
FR0012333284
Symbol
ABVX
Sector
Industry

Key metrics

Market capitalization €353.88m
Enterprise Value €305.86m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.71
Revenue (TTM) Revenue €0.00
EBIT (operating result TTM) EBIT €-185.43m
Free Cash Flow (TTM) Free Cash Flow €-154.23m
EPS (TTM) EPS €-2.80
P/E forward negative
P/S forward 49.71
EV/Sales forward 42.96
Show more

Is Abivax SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Abivax SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Abivax SA forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Abivax SA forecast:

Buy
92%
Hold
8%

Financial data from Abivax SA

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.10 1.10
55% 55%
-
-1.10 -1.10
55% 55%
-
- Selling and Administrative Expenses 37 37
34% 34%
-
- Research and Development Expense 147 147
42% 42%
-
-184 -184
40% 40%
-
- Depreciation and Amortization 1.10 1.10
55% 55%
-
EBIT (Operating Income) EBIT -185 -185
40% 40%
-
Net Profit -176 -176
19% 19%
-

In millions EUR.

Don't miss a Thing! We will send you all news about Abivax SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Abivax SA Stock News

AD HOC NEWS
10 days ago
ABIVAX / FR0012333284
AD HOC NEWS
2 months ago
ABIVAX / FR0012333284
AD HOC NEWS
3 months ago
ABIVAX / FR0012333284
More Abivax SA News

Company Profile

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development comprise of vaccine for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Head office France
CEO Marc Garidel
Employees 69
Founded 2013
Website www.abivax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today